{"id":8769,"date":"2026-10-26T17:18:09","date_gmt":"2026-10-26T11:48:09","guid":{"rendered":"https:\/\/www.wittytrades.com\/market-news\/mankind-share-price-today-2026-10-26\/"},"modified":"2026-10-26T19:15:05","modified_gmt":"2026-10-26T13:45:05","slug":"mankind-share-price-today-2026-10-26","status":"publish","type":"post","link":"https:\/\/www.wittytrades.com\/market-news\/mankind-share-price-today-2026-10-26\/","title":{"rendered":"Mankind Pharma Share Price Today: Why MANKIND Is Rising 4.49% | 26 October 2026"},"content":{"rendered":"<style id=\"wt-article-style-v4\">:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) { color:#30475c; font-size:16px; line-height:1.65; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *::before, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *::after { box-sizing:border-box; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-copy { font-size:16px !important; line-height:1.65 !important; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-prose .wt-copy { margin-bottom:15px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-market-date { font-size:13px !important; line-height:1.55; color:#566b80; background:#f2f6f9; border:1px solid #dde6ec; border-left:4px solid #2e7db2; border-radius:6px; padding:8px 11px; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { display:grid; grid-template-columns:repeat(6,minmax(0,1fr)); gap:7px; margin:8px 0 16px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div { padding:10px !important; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:first-child { font-size:11px !important; line-height:1.45; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:last-child { font-size:14px !important; line-height:1.5; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card { padding:14px 16px; min-width:0; overflow-wrap:anywhere; margin:14px 0 18px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-title { font-size:16px; font-weight:800; line-height:1.45; color:#17324d; margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-date { font-size:13px; line-height:1.5; color:#566b80; margin-bottom:9px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-body { font-size:16px; line-height:1.6; color:#34495d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-body .wt-copy:last-child { margin-bottom:0 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid { display:grid; grid-template-columns:repeat(2,minmax(0,1fr)); gap:12px; margin:12px 0 18px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid > .wt-card { margin:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid > :only-child { grid-column:1 \/ -1; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-metrics { grid-template-columns:repeat(3,minmax(0,1fr)); margin:10px 0 12px; gap:10px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-metric { background:#fff; border:1px solid #e1e8ef; border-radius:8px; padding:10px 12px; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-label { display:block; font-size:12px; font-weight:700; color:#566b80; line-height:1.5; margin-bottom:3px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-value { font-size:18px; font-weight:800; line-height:1.45; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-note { display:block; font-size:13px; color:#566b80; line-height:1.55; margin-top:4px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-source-note { margin:9px 0 4px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-source { display:inline-block; font-size:13px; line-height:1.5; margin-top:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { display:grid; grid-template-columns:2fr 1fr 1.2fr 1.2fr; gap:14px; padding:12px 0; border-bottom:1px solid #c9dbef; align-items:start; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row:last-of-type { border-bottom:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row strong { font-size:15px; line-height:1.5; display:block; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row > div { min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds { grid-template-columns:repeat(3,minmax(0,1fr)); margin:12px 0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card { padding:12px; background:#fff !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-title { font-size:14px; font-weight:700; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-body { font-size:14px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-brokerage { grid-template-columns:1fr; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-broker-facts { display:flex; flex-wrap:wrap; gap:14px 28px; margin:7px 0 12px; padding-bottom:10px; border-bottom:1px solid #cbd8ea; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-broker-facts strong { font-size:16px; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-list { font-size:16px !important; line-height:1.65; margin:0 0 12px; padding-left:20px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-list li { margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-card { background:#f7fbff !important; border-color:#cfe1f2 !important; border-left-color:#2e7db2 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-card-title { color:#1f4d70; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-list { margin-bottom:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card { background:#f5fbfd !important; border-color:#c9d9e7 !important; border-left:5px solid #1f7b92 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card-title { color:#174c5d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card-body > strong { display:block; margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta { padding:18px 19px; margin:22px 0; border-radius:13px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-title { font-size:19px; font-weight:800; line-height:1.4; margin-bottom:7px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow { background:linear-gradient(135deg,#ffe873,#ffd64a); border:1px solid #e3b600; box-shadow:0 8px 18px rgba(59,48,0,.09); }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow .wt-cta-title { color:#10233f !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow .wt-cta-copy { color:#27364b !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark { background:#10233f; box-shadow:0 9px 22px rgba(16,35,63,.18); }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-title { color:#fff !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-copy { color:#dce6f1 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-copy { font-size:16px !important; line-height:1.6; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-button { display:inline-block; background:#10233f; color:#fff !important; padding:10px 17px; border-radius:7px; text-decoration:none !important; font-size:15px; font-weight:800; line-height:1.5; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-button { background:#ffe36e; color:#10233f !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-faq h3 { color:#173b58 !important; font-size:17px !important; line-height:1.45; margin:18px 0 6px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) > p:last-child { font-size:13px; line-height:1.55; color:#606b78; border-top:1px solid #e1e7ef; padding-top:13px; margin-top:16px; }\n@media (max-width:960px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { grid-template-columns:repeat(3,minmax(0,1fr)); }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { grid-template-columns:1.7fr 1fr 1.2fr 1.2fr; gap:10px; }\n}\n@media (max-width:650px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid { grid-template-columns:1fr; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-metrics { grid-template-columns:repeat(2,minmax(0,1fr)); }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card { padding:14px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { grid-template-columns:repeat(2,minmax(0,1fr)); gap:10px 14px; padding:12px 0; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-person, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row > div:last-child { grid-column:1 \/ -1; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta { padding:17px 15px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-title { font-size:18px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div { padding:9px !important; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-title, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-body { font-size:15px; }\n}\n@media (max-width:420px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { grid-template-columns:repeat(2,minmax(0,1fr)); }\n}<\/p>\n<p>:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div {border:1px solid #dde6ee;border-radius:8px;background:#f9fbfd;}\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:last-child {font-weight:800;color:#17324d;}\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) h2 {font-size:24px !important;line-height:1.35 !important;margin:28px 0 14px !important;color:#173b58;}\n<\/style>\n<div class=\"wt-article-v4\" data-witty-phase=\"live\" data-article-version=\"4\">\n<p class=\"wt-market-date\"><strong>NSE: MANKIND<\/strong> \u00b7 26 October 2026<\/p>\n<div class=\"wt-price-strip\">\n<div>\n<div>Price<\/div>\n<div>\u20b92,312.00<\/div>\n<\/div>\n<div>\n<div>Change<\/div>\n<div>+4.49%<\/div>\n<\/div>\n<div>\n<div>High \/ Low<\/div>\n<div>\u20b92,333.90 \/ \u20b92,215.00<\/div>\n<\/div>\n<div>\n<div>Prev. Close<\/div>\n<div>\u20b92,212.60<\/div>\n<\/div>\n<div>\n<div>Volume<\/div>\n<div>10.25 lakh<\/div>\n<\/div>\n<div>\n<div>Price as of<\/div>\n<div>26 October 2026 \u00b7 03:30 PM IST<\/div>\n<\/div>\n<\/div>\n<div class=\"wt-takeaways\">\n<div class=\"wt-card\" data-card=\"research\" style=\"background:#f4f8fd;border:1px solid #cbd8ea;border-left:4px solid #466fa5;border-radius:10px\">\n<div class=\"wt-card-title\">Key Takeaways<\/div>\n<div class=\"wt-card-body\">\n<ul class=\"wt-list\">\n<li>Mankind Pharma Limited shares advanced 4.49% on Monday, closing at \u20b92,312.00 after trading within a daily range of \u20b92,215.00 and \u20b92,333.90.<\/li>\n<li>The company announced a strategic acquisition of a majority stake in Armed Cell Therapeutics, marking its entry into next-generation CAR-T therapies. Management noted that the transaction aims to strengthen the company&#x27;s R&amp;D capabilities for future growth in specialized oncology treatments.<\/li>\n<li>Trading volume was 1.65 times the 20-day average daily volume.<\/li>\n<\/ul>\n<\/div>\n<\/div>\n<\/div>\n<h2>Why is Mankind Pharma share price rising on 26 October 2026?<\/h2>\n<div class=\"wt-prose\">\n<p class=\"wt-copy\">Mankind Pharma Limited shares advanced 4.49% on Monday, closing at \u20b92,312.00 after trading within a daily range of \u20b92,215.00 and \u20b92,333.90.<\/p>\n<p class=\"wt-copy\">The broader market and healthcare sector provided supportive tailwinds during the trading session. The benchmark Nifty rose by 0.68%, while the Nifty Pharma sector index outperformed with a gain of 1.76%. Mankind Pharma&#x27;s upward price action contributed to the broader sectoral momentum, building on a modest 5-day return of 1.60% despite a 20-day trailing loss of 7.52%.<\/p>\n<p class=\"wt-copy\">The positive price movement coincided with the release of the company&#x27;s financial results for the second quarter and half year ended September 30, 2026. Mankind Pharma reported strong operational performance, with consolidated revenue from operations growing 17.3% year-on-year to \u20b94,338 crore and profit after tax surging 37.7% to \u20b9716 crore. Management highlighted robust domestic business growth and continued outperformance in chronic and acute therapeutic segments as key drivers of the period&#x27;s results.<\/p>\n<p class=\"wt-copy\">10.25 lakh shares traded by 26 October 2026 \u00b7 03:30 PM IST. This compares with a 20-day average daily volume of 6.21 lakh shares (1.65 times). The five-day average daily volume was 7.39 lakh shares. Separately, the NSE report for 26 October 2026 showed 4.56 lakh shares delivered, representing 44.46% of that day\u2019s traded volume. The same report recorded 56,520 trades.<\/p>\n<\/div>\n<div class=\"wt-likely-reason\">\n<div class=\"wt-card\" data-card=\"research\" style=\"background:#f4f8fd;border:1px solid #cbd8ea;border-left:4px solid #466fa5;border-radius:10px\">\n<div class=\"wt-card-title\">Likely Reason<\/div>\n<div class=\"wt-card-body\"><strong>strong Q2 financial results and sector momentum<\/strong><\/p>\n<p class=\"wt-copy\">The stock&#x27;s 4.49% gain was supported by heavy trading volumes and favourable sectoral performance, directly coinciding with the announcement of strong Q2 FY27 financial results that showed robust revenue and profit growth.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<aside class=\"wt-cta wt-cta-yellow\">\n<div class=\"wt-cta-title\">Research the Market \u2014 Not Just the Headline<\/div>\n<p class=\"wt-cta-copy\">Explore WittyTrades research across market segments.<\/p>\n<p><a class=\"wt-cta-button\" href=\"https:\/\/www.wittytrades.com\/Segments.html\">Explore WittyTrades Research \u2192<\/a><\/aside>\n<h2>Latest Company Developments<\/h2>\n<div class=\"wt-grid wt-grid-news\">\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Acquisition of Majority Stake in Armed Cell Therapeutics<\/div>\n<div class=\"wt-card-date\">16 October 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">The company announced a strategic acquisition of a majority stake in Armed Cell Therapeutics, marking its entry into next-generation CAR-T therapies. Management noted that the transaction aims to strengthen the company&#x27;s R&amp;D capabilities for future growth in specialized oncology treatments.<\/p>\n<p class=\"wt-copy\">This strategic transaction expands Mankind Pharma&#x27;s technological capabilities and product pipeline into advanced cellular therapies.<\/p>\n<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Earnings \/ operating update<\/div>\n<div class=\"wt-card-date\">18 September 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Mankind Pharma Limited has submitted the Exchange a copy Srutinizers report of Postal Ballot. Further, the company has informed the Exchange regarding voting results.<\/p>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/MANKIND1_17092026190722_Covering_SD.pdf\" rel=\"noopener\">Original source \u2192<\/a><\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Investment \/ acquisition update<\/div>\n<div class=\"wt-card-date\">16 October 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">a press release dated October 15, 2026, titled &quot;Press Release titled Mankind Pharma to Acquire Majority Stake in Armed Cell Therapeutics, Marking Strategic Entry into Next-Generation CAR-T Therapies &quot;.<\/p>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/MANKIND1_15102026193306_Outcomefinalsd.pdf\" rel=\"noopener\">Original source \u2192<\/a><\/div>\n<\/div>\n<\/div>\n<h2>Ownership &amp; Transaction Activity<\/h2>\n<div class=\"wt-grid wt-grid-ownership\">\n<div class=\"wt-card\" data-card=\"ownership\" style=\"background:#fff8e8;border:1px solid #ecd39e;border-left:4px solid #cc922c;border-radius:10px\">\n<div class=\"wt-card-title\">Shareholding<\/div>\n<div class=\"wt-card-date\">As of 30 September 2026<\/div>\n<div class=\"wt-card-body\">\n<div class=\"wt-grid wt-grid-metrics\">\n<div class=\"wt-metric\">\n<div class=\"wt-label\">Promoter holding<\/div>\n<div class=\"wt-value\">72.62%<\/div>\n<div class=\"wt-note\">72.63% on 30 June 2026<\/div>\n<\/div>\n<div class=\"wt-metric\">\n<div class=\"wt-label\">FII\/FPI<\/div>\n<div class=\"wt-value\">9.37%<\/div>\n<div class=\"wt-note\">9.45% on 30 June 2026<\/div>\n<\/div>\n<div class=\"wt-metric\">\n<div class=\"wt-label\">Institutional holding<\/div>\n<div class=\"wt-value\">24.93%<\/div>\n<div class=\"wt-note\">24.84% on 30 June 2026<\/div>\n<\/div>\n<\/div>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/xbrl\/SHP_1740145_16102026052126_WEB.xml\" rel=\"noopener\">NSE shareholding filing \u2192<\/a><\/div>\n<\/div>\n<\/div>\n<h2>Mutual Fund Holdings<\/h2>\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">Mutual-fund ownership<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Mutual funds held 11.31% on 30 September 2026. This compares with 10.87% on 30 June 2026, a change of +0.44 percentage points.<\/p>\n<p class=\"wt-copy\">The filing reported 36 MF\/UTI holders.<\/p>\n<div class=\"wt-grid wt-grid-funds\">\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">NIPPON LIFE INDIA TRUSTEE LTD-A\/C NIPPON INDIA RET<\/div>\n<div class=\"wt-card-date\">30 September 2026<\/div>\n<div class=\"wt-card-body\">1.01 crore shares \u00b7 2.45%<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">SBI ESG EXCLUSIONARY STRATEGY FUND<\/div>\n<div class=\"wt-card-date\">30 September 2026<\/div>\n<div class=\"wt-card-body\">61.45 lakh shares \u00b7 1.49%<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">ADITYA BIRLA SUN LIFE MUTUAL FUND &#8211; ADITYA BIRLA S<\/div>\n<div class=\"wt-card-date\">30 September 2026<\/div>\n<div class=\"wt-card-body\">49.97 lakh shares \u00b7 1.21%<\/div>\n<\/div>\n<\/div>\n<div class=\"wt-note wt-source-note\">These are quarterly holdings, rather than purchases or sales on the article date.<\/div>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/xbrl\/SHP_1740145_16102026052126_WEB.xml\" rel=\"noopener\">NSE shareholding filing \u2192<\/a><\/div>\n<\/div>\n<h2>What to Watch Next<\/h2>\n<ul class=\"wt-list\">\n<li>Management commentary and guidance provided during the upcoming earnings conference call<\/li>\n<li>Post-earnings delivery volume sustainability relative to the 20-day average<\/li>\n<li>Integration progress and R&amp;D updates regarding the recently announced Armed Cell Therapeutics acquisition<\/li>\n<li>Continued market share trends across key chronic and acute therapeutic brands<\/li>\n<\/ul>\n<h2>Other Dated Coverage<\/h2>\n<ul class=\"wt-list\">\n<li><a href=\"https:\/\/www.wittytrades.com\/market-news\/mankind-share-price-today-2026-10-23\/\">Mankind Pharma Share Price Today: Why MANKIND Is Falling 2.77% | 23 October 2026 \u2014 23 October 2026<\/a><\/li>\n<li><a href=\"https:\/\/www.wittytrades.com\/market-news\/mankind-share-price-today-2026-10-16\/\">Mankind Pharma in Focus After Acquiring Majority Stake in Armed Cell Therapeutics | 16 October 2026 \u2014 16 October 2026<\/a><\/li>\n<li><a href=\"https:\/\/www.wittytrades.com\/market-news\/mankind-share-price-today-2026-10-14\/\">Mankind Pharma Share Price Today: Why MANKIND Is Falling 2.47% | 14 October 2026 \u2014 14 October 2026<\/a><\/li>\n<\/ul>\n<p><a href=\"https:\/\/www.wittytrades.com\/market-news\/tag\/mankind\/\">More Mankind Pharma news and dated analysis \u2192<\/a><\/p>\n<aside class=\"wt-cta wt-cta-dark\">\n<div class=\"wt-cta-title\">Looking for Research-Backed Market Opportunities?<\/div>\n<p class=\"wt-cta-copy\">Explore WittyTrades research across market segments.<\/p>\n<p><a class=\"wt-cta-button\" href=\"https:\/\/www.wittytrades.com\/Segments.html\">Explore WittyTrades Research \u2192<\/a><\/aside>\n<h2>Frequently Asked Questions<\/h2>\n<div class=\"wt-faq\">\n<h3>What is the latest Mankind Pharma company news?<\/h3>\n<p class=\"wt-copy\">The company announced a strategic acquisition of a majority stake in Armed Cell Therapeutics, marking its entry into next-generation CAR-T therapies. Management noted that the transaction aims to strengthen the company&#x27;s R&amp;D capabilities for future growth in specialized oncology treatments.<\/p>\n<h3>How strong was Mankind Pharma\u2019s trading volume?<\/h3>\n<p class=\"wt-copy\">10.25 lakh shares traded, 1.65 times the 20-day average daily volume. The price and volume data are dated 26 October 2026 \u00b7 03:30 PM IST.<\/p>\n<h3>Do the mutual-fund figures show buying today?<\/h3>\n<p class=\"wt-copy\">They show holdings on 30 September 2026. Quarterly holdings do not identify purchases made on the article date.<\/p>\n<\/div>\n<p><strong>Research &amp; analysis:<\/strong> <a href=\"https:\/\/www.wittytrades.com\/About_Us.html\">WittyTrades Research Desk<\/a><br \/><strong>Reviewed by:<\/strong> <a href=\"https:\/\/www.wittytrades.com\/About_Us.html\">Mohanish Sanghavi \u2014 SEBI Registered Research Analyst<\/a><\/p>\n<p>Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.<\/p>\n<\/div>\n<p><script type=\"application\/ld+json\">{\"@context\": \"https:\/\/schema.org\", \"@graph\": [{\"@type\": \"WebSite\", \"@id\": \"https:\/\/www.wittytrades.com\/#website\", \"url\": \"https:\/\/www.wittytrades.com\/\", \"name\": \"WittyTrades\", \"publisher\": {\"@id\": \"https:\/\/www.wittytrades.com\/#organization\"}, \"inLanguage\": \"en-IN\"}, {\"@type\": \"Organization\", \"@id\": \"https:\/\/www.wittytrades.com\/#organization\", \"name\": \"WittyTrades\", \"alternateName\": \"Witty Networks\", \"url\": \"https:\/\/www.wittytrades.com\/\", \"telephone\": \"+91-22-48972020\", \"identifier\": [{\"@type\": \"PropertyValue\", \"propertyID\": \"SEBI Research Analyst Registration\", \"value\": \"INH000008172\"}, {\"@type\": \"PropertyValue\", \"propertyID\": \"BSE Research Analyst Code\", \"value\": \"5430\"}]}, {\"@type\": \"Organization\", \"@id\": \"https:\/\/www.wittytrades.com\/#research-desk\", \"name\": \"WittyTrades Research Desk\", \"url\": \"https:\/\/www.wittytrades.com\/About_Us.html\", \"parentOrganization\": {\"@id\": \"https:\/\/www.wittytrades.com\/#organization\"}}, {\"@type\": \"Person\", \"@id\": \"https:\/\/www.wittytrades.com\/About_Us.html#mohanish-sanghavi\", \"name\": \"Mohanish Sanghavi\", \"jobTitle\": \"SEBI Registered Research Analyst\", \"url\": \"https:\/\/www.wittytrades.com\/About_Us.html\", \"worksFor\": {\"@id\": \"https:\/\/www.wittytrades.com\/#organization\"}, \"identifier\": {\"@type\": \"PropertyValue\", \"propertyID\": \"SEBI Research Analyst Registration\", \"value\": \"INH000008172\"}}, {\"@type\": \"NewsArticle\", \"@id\": \"https:\/\/www.wittytrades.com\/market-news\/mankind-share-price-today-2026-10-26\/#article\", \"mainEntityOfPage\": {\"@type\": \"WebPage\", \"@id\": \"https:\/\/www.wittytrades.com\/market-news\/mankind-share-price-today-2026-10-26\/\"}, \"headline\": \"Mankind Pharma Share Price Today: Why MANKIND Is Rising 4.49% | 26 October 2026\", \"description\": \"Mankind Pharma share price rose 4.49% to \u20b92,312.00 today. See why MANKIND is rising, volume context, company developments and what to watch next.\", \"datePublished\": \"2026-10-26T11:48:09Z\", \"dateModified\": \"2026-10-26T19:14:56.982554+05:30\", \"author\": {\"@id\": \"https:\/\/www.wittytrades.com\/#research-desk\"}, \"reviewedBy\": {\"@id\": \"https:\/\/www.wittytrades.com\/About_Us.html#mohanish-sanghavi\"}, \"publisher\": {\"@id\": \"https:\/\/www.wittytrades.com\/#organization\"}, \"isPartOf\": {\"@id\": \"https:\/\/www.wittytrades.com\/#website\"}, \"about\": {\"@type\": \"Thing\", \"name\": \"Mankind Pharma\", \"identifier\": {\"@type\": \"PropertyValue\", \"propertyID\": \"NSE Symbol\", \"value\": \"MANKIND\"}}, \"inLanguage\": \"en-IN\", \"isAccessibleForFree\": true, \"image\": [\"https:\/\/www.wittytrades.com\/market-news\/wp-content\/uploads\/2026\/10\/mankind-company-news-2026-10-26.jpg\"]}]}<\/script><!-- wt-article-record:{\"news_events\":[{\"title\":\"Investor Presentation\",\"summary\":\"Investor Presentation\",\"source\":\"NSE\",\"published\":\"26-Oct-2026 15:29:19\",\"source_type\":\"official filing\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/MANKIND1_26102026152911_CoverPRsd.pdf\",\"disclosure_text\":\"October 26, 2026 BSE Limited P J Towers, Dalal Street, Mumbai \u2013 400 001 Scrip Code: 543904 National Stock Exchange of India Limited Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai \u2013 400 051 Symbol: MANKIND Dear Sir\/ Madam, Subject: Press Release \u2013 Q2 & H1 FY27 Ref: Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 Please find enclosed herewith the Press Release on Financial Results of the Company for the Q2 & H1 FY27. The above-mentioned Press Release is also being uploaded on the website of the company i.e. www.mankindpharma.com. Yo u are requested to kindly take the above information on your records. Thanking You, Yours Faithfully, For Mankind Pharma Limited Hitesh Kumar Jain Company Secretary & Compliance Officer Encl.: A\/a Press Release Strong Revenue growth of 17%; EBITDA up by 27% and PAT up by 38%; Domestic Business\u00b9 delivered robust growth of 16% New Delhi, India, 26th October, 202 6: Mankind Pharma (BSE: 543904 | NSE: MANKIND) India\u2019s fourth largest pharmaceutical Company today announced its financial results for the second quarter and half year ended 30th September 2026. The information mentioned in this release is based on consolidated financial statements. 1. Domestic business excluding Consumer Healthcare || 2. Ex-Tirzepatide Revenues Dom. Revenue1 EBITDA Q2 FY27 INR 4,338 Crore 17% YoY INR 3,428 Crore 16% YoY INR 1,175 Crore 27% YoY Mr. Rajeev Juneja \u2013 Vice Chairman & Managing Director \uf0b7 Revenue grew ~17% YoY with EBITDA margins improving by 210 bps to 27.1% \uf0b7 Strong domestic business1 growth of 15.9% led by 1.2x volume outperformance to IPM, further supported by: \uf0fc Mid-teen growth in Mankind Domestic with 1.1x Chronic outperformance 2, led by growth of 19% in Cardiac and 16% in Anti-diabetes \uf0fc Acute outperformance of 1.1x, led by 19% growth in Gastro, 26% in VMN \uf0fc Steady double digit growth in BSV domestic specialty business \uf0b7 International business grew 33%, while OTC witnessed muted growth in Q2 \uf0b7 Our disciplined execution and strengthening business fundamentals resulted in strong performance. Our recent acquisition of Armed Cell Therapeutics, marks strategic entry into Next-Generation CAR-T therapies, strengthening R&D capabilities for future growth. Revenues Dom. Revenue1 EBITDA H1 FY27 INR 8,368 Crore 15% YoY INR 6,608 Crore 13% YoY INR 2,235 Crore 26% YoY Press Release Q2 FY27 Performance Summary \uf0b7 Revenue from Operations at INR 4,338 Cr, up by 17.3%YoY o Domestic revenue at INR 3,657 Cr, up 14.8%, Exports at INR 681 Cr, up 32.7% YoY \uf0b7 EBITDA margin of 27.1%, up by 210 bps YoY and PAT margin of 16.5%, up 240 bps YoY \uf0b7 Diluted EPS1 of INR 17.2, up 38.9% YoY (FV Re.1) H1 FY27 Performance Summary \uf0b7 Revenue from Operations at INR 8,368 Cr, up by 15.1%YoY o Domestic revenue at INR 7,082 Cr, up 12.7%, Exports at INR 1,286 Cr, up 31.0% YoY \uf0b7 EBITDA margin of 26.7%, up by 230 bps YoY and PAT margin of 15.4%, up 210 bps YoY \uf0b7 Diluted EPS1 of INR 30.9, up 34.6% YoY (FV Re.1) 1. Diluted EPS not annualised Domestic Business1 \uf0b7 Domestic revenue (ex CH)2 increased 15.9% YoY driven by strong double digit growth in both Mankind and BSV specialty business \uf0b7 Secondary sales growth of 15.7 % vs 14.2% IPM3 in Q2FY27 indicating a 1.1x outperformance to IPM led by: \uf0fc 1.1x outperformance in chronic3 growth supported by 18.7% in Cardiac and 15.8 % in Anti-diabetes \uf0fc 1.1x outperformance in acute driven by Gastro ( 1.3x ), VMN 1.4x); Anti -infectives also recovering QoQ (5.4% in Q2FY27 vs 3.6% in Q1FY27) \uf0b7 Strong growth in key focused brands: \uf0fc Acute brands like Pantakind (31%), Dydroboon (19%), Cefakind CV (18%), Nurokind LC (18%) in Q2FY27 \uf0fc Chronic brands like Pangraf (60%), Placida (28%), Telmikind AM (16%), Glizid M (15%) \uf0fc Healthy growth in BSVs key brands - Humog (51%), Lonopin (45 %), Anti D (37 %) and ASVS (45%) \uf0fc Brands with sales above Rs 50 crore increased to 63 in MAT Sep\u201926 from 54 in FY26, while brands with sales over Rs 100 crore rose to 26 from 22 \uf0b7 Consistently maintained #1 rank over last 9 years with prescription share of 15.2% and prescriber penetration of 84.4% in MAT Aug\u201926 1.As per IQVIA Sep-2026 \/\/ 2.Denotes reported number\/\/ 3. Ex-Tirzepatide Consumer Healthcare Business1 \uf0b7 Revenue growth impacted by slower offtake in category for the industry and some regional impact in East and South \uf0b7 Despite softer growth, we gained market share in key Brands \u2013 Manforce, and Preganews \uf0b7 MT & E-Com share increased to 18% in Q2FY27 as compared to 12% in Q2FY26 supported by 55% growth \uf0b7 Healthy growth in secondary sales for Preganews and Ova news of 14 % and 10 % YoY respectively in Q2 FY27 1 As per IQVIA \/ IQVIA Retail Sep-2026 Press Release Exports \uf0b7 International revenue increased by 33% in Q2FY27 driven by strong growth in both Mankind and BSV International \uf0b7 Mankind has launched 1 new product in Q2FY27 taking the total launched products to 50 in US Consolidated Profit & Loss Account Particulars (In INR Crore) Q2 FY27 Q2 FY26 YoY% Q1 FY27 QoQ% Revenue from Operations 4,338 3,697 17.3% 4,031 7.6% Gross Margins % 72.2% 71.3% 90 bps 72.8% (60 bps) EBITDA 1,175 924 27.2% 1,060 10.8% EBITDA Margin % 27.1% 25.0% 210 bps 26.3% 80 bps PAT 716 520 37.7% 574 24.7% PAT Margin % 16.5% 14.1% 240 bps 14.2% 230 bps Particulars (In INR Crore) H1 FY27 H1 FY26 YoY% Revenue from Operations 8,368 7,268 15.1% Gross Margins % 72.5% 70.9% 160 bps EBITDA 2,235 1,774 26.0% EBITDA Margin % 26.7% 24.4% 230 bps PAT 1,290 965 33.7% PAT Margin % 15.4% 13.3% 210 bps Segmental Revenue Break Up Particulars (In INR Crore) Q2 FY27 Q2 FY26 YoY% Q1 FY27 QoQ% Domestic 3,657 3,184 14.8% 3,426 6.7% \uf0b7 Domestic (Ex-CH) 3,428 2,958 15.9% 3,180 7.8% \uf0b7 Consumer Healthcare 229 226 1.2% 246 (7.0%) Exports 681 513 32.7% 605 12.6% Total 4,338 3,697 17.3% 4,031 7.6% Particulars (In INR Crore) H1 FY27 H1 FY26 YoY% Domestic 7,082 6,285 12.7% \uf0b7 Domestic (Ex-CH) 6,608 5,822 13.5% \uf0b7 Consumer Healthcare 475 463 2.6% Exports 1,286 982 31.0% Total 8,368 7,268 15.1% Press Release Earning Concall Details Date 26th October, 2026 Time 05:00 pm \u2013 06:00 pm IST Zoom Link Click here About Mankind Pharma Mankind Pharma (BSE: 543904 | NSE: MANKIND) is one of the largest pharmaceutical company in India, which focuses on the domestic market with its Pan India presence. Mankind operates at the intersection of the Indian pharmaceutical formulations and consumer healthcare sectors with the aim of providing quality products at affordable prices. The company is a leading player in the domestic pharmaceuticals business present across acute and chronic therapeutic areas including anti -infectives, cardiovascular, gastrointes tinal, antidiabetic, neuro\/CNS, gynaecology, VMN and respiratory, among others with a strategy to increase chronic presence going ahead. In the consumer healthcare business, the company operates in the condoms, pregnancy detection, emergency contraceptives, antacid powders, vitamin and mineral supplements and anti-acne preparations categories, among others, with several category -leading brands. Following the acquisition of BSV, Mankind Pharma has further strengthened its leadership in the domestic women\u2019s h ealth segment. Mankind's distribution network includes a robust field for ce of 18,500+ professionals, and a reach extending to over five lakh doctors across urban and rural markets. The company has 32 manufacturing facilities in India manufacturing a wide range of dosage forms, including tablets, capsules, syrups, vials, ampoules, blow fill seal, soft and hard gels, eye drops, creams, contraceptives and other over -the-counter products. Mankind has a consistent track record of product innovation through 7 dedicated R&D facilities backed by more than 740 scientists. For more information, visit www.mankindpharma.com Safe Harbour Statement The statements, are as on date and may contain forward -looking statements like the words \u201cbelieve\u201d, \u201cexpects\u201d, \u201canticipate\u201d, \u201caim\u201d, \u201cwill likely result\u201d, \u201cWould\u201d, \u201cwill continue\u201d, \u201ccontemplate\u201d \u201cintends\u201d, \u201cplans\u201d, \u201cestimates\u201d, \u201cseek to\u201d, \u201cfuture\u201d, \u201cobjective\u201d, \u201cprojects\u201d, \u201cgoal\u201d, \u201clikely\u201d, \u201cProject\u201d, \u201cshould\u201d, \u201cpotential\u201d \u201cwill\u201d , \u201cmay\u201d, \u201ctargeting\u201d or other words of similar expressions\/ meaning regarding the financial position, business strategy, plans, targets and objectives of the Company. Such forward\u2010 looking statements involve known and unknown risks which may cause actual results, performance or achievements to be materially different from the results or achievements expressed or implied. The risks and uncertainties inter-alia, relating to these statements include (i) cash flow projections, (ii) industry and market conditions; (iii) ability to manage growth; (iv) competition; (v) government policies and regulations; (vi) obtaining regulatory approvals; (vii) domestic & international economic Press Release conditions such as interest rate & currency exchange fluctuations; (viii) political, economic, legal and social conditions in India\/ elsewhere; (ix) technological advances; (x) claims and concerns about product safety and efficacy; (xi) domestic and foreign healthcare reforms; (xii) inability to build production capacity; (xiii) unavailabi lity of raw materials and failure to gain market acceptance The Company and its subsidiaries shall not have any responsibility or liability whatsoever for any loss howsoever arising from this presentation or its contents or otherwise arising in connection therewith. Also, Company assume no responsibility to publicly amend, modify or revise any forward looking statements, on the basis of any subsequent developments, information or events, or otherwise. For Queries Contact Mankind Pharma - Investor Relations Prakash Agarwal Email address: investor.relations@mankindpharma.com Contact Number: +91-11-46846700 Mankind Pharma - Corporate Communication Natasha Raj Email address: natasha.raj@mankindpharma.com Contact Number: 011-46846700 Ext: 3201 Adfactors PR - Investor Relations \/ Public Relations Smit Shah \/ Apoorva Sharma Email address: smit.shah@adfactorspr.com \/ apoorva.sharma@adfactorspr.com Contact Number: +91 9870789596 \/ +91 9999739452\"},{\"title\":\"Press Release\",\"summary\":\"a press release dated October 26, 2026, titled \\\"Press Release on Financial Results for Q2 & H1 FY27\\\".\",\"source\":\"NSE\",\"published\":\"26-Oct-2026 15:23:58\",\"source_type\":\"official filing\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/MANKIND1_26102026152348_CoverPRsd.pdf\",\"disclosure_text\":\"October 26, 2026 BSE Limited P J Towers, Dalal Street, Mumbai \u2013 400 001 Scrip Code: 543904 National Stock Exchange of India Limited Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai \u2013 400 051 Symbol: MANKIND Dear Sir\/ Madam, Subject: Press Release \u2013 Q2 & H1 FY27 Ref: Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 Please find enclosed herewith the Press Release on Financial Results of the Company for the Q2 & H1 FY27. The above-mentioned Press Release is also being uploaded on the website of the company i.e. www.mankindpharma.com. Yo u are requested to kindly take the above information on your records. Thanking You, Yours Faithfully, For Mankind Pharma Limited Hitesh Kumar Jain Company Secretary & Compliance Officer Encl.: A\/a Press Release Strong Revenue growth of 17%; EBITDA up by 27% and PAT up by 38%; Domestic Business\u00b9 delivered robust growth of 16% New Delhi, India, 26th October, 202 6: Mankind Pharma (BSE: 543904 | NSE: MANKIND) India\u2019s fourth largest pharmaceutical Company today announced its financial results for the second quarter and half year ended 30th September 2026. The information mentioned in this release is based on consolidated financial statements. 1. Domestic business excluding Consumer Healthcare || 2. Ex-Tirzepatide Revenues Dom. Revenue1 EBITDA Q2 FY27 INR 4,338 Crore 17% YoY INR 3,428 Crore 16% YoY INR 1,175 Crore 27% YoY Mr. Rajeev Juneja \u2013 Vice Chairman & Managing Director \uf0b7 Revenue grew ~17% YoY with EBITDA margins improving by 210 bps to 27.1% \uf0b7 Strong domestic business1 growth of 15.9% led by 1.2x volume outperformance to IPM, further supported by: \uf0fc Mid-teen growth in Mankind Domestic with 1.1x Chronic outperformance 2, led by growth of 19% in Cardiac and 16% in Anti-diabetes \uf0fc Acute outperformance of 1.1x, led by 19% growth in Gastro, 26% in VMN \uf0fc Steady double digit growth in BSV domestic specialty business \uf0b7 International business grew 33%, while OTC witnessed muted growth in Q2 \uf0b7 Our disciplined execution and strengthening business fundamentals resulted in strong performance. Our recent acquisition of Armed Cell Therapeutics, marks strategic entry into Next-Generation CAR-T therapies, strengthening R&D capabilities for future growth. Revenues Dom. Revenue1 EBITDA H1 FY27 INR 8,368 Crore 15% YoY INR 6,608 Crore 13% YoY INR 2,235 Crore 26% YoY Press Release Q2 FY27 Performance Summary \uf0b7 Revenue from Operations at INR 4,338 Cr, up by 17.3%YoY o Domestic revenue at INR 3,657 Cr, up 14.8%, Exports at INR 681 Cr, up 32.7% YoY \uf0b7 EBITDA margin of 27.1%, up by 210 bps YoY and PAT margin of 16.5%, up 240 bps YoY \uf0b7 Diluted EPS1 of INR 17.2, up 38.9% YoY (FV Re.1) H1 FY27 Performance Summary \uf0b7 Revenue from Operations at INR 8,368 Cr, up by 15.1%YoY o Domestic revenue at INR 7,082 Cr, up 12.7%, Exports at INR 1,286 Cr, up 31.0% YoY \uf0b7 EBITDA margin of 26.7%, up by 230 bps YoY and PAT margin of 15.4%, up 210 bps YoY \uf0b7 Diluted EPS1 of INR 30.9, up 34.6% YoY (FV Re.1) 1. Diluted EPS not annualised Domestic Business1 \uf0b7 Domestic revenue (ex CH)2 increased 15.9% YoY driven by strong double digit growth in both Mankind and BSV specialty business \uf0b7 Secondary sales growth of 15.7 % vs 14.2% IPM3 in Q2FY27 indicating a 1.1x outperformance to IPM led by: \uf0fc 1.1x outperformance in chronic3 growth supported by 18.7% in Cardiac and 15.8 % in Anti-diabetes \uf0fc 1.1x outperformance in acute driven by Gastro ( 1.3x ), VMN 1.4x); Anti -infectives also recovering QoQ (5.4% in Q2FY27 vs 3.6% in Q1FY27) \uf0b7 Strong growth in key focused brands: \uf0fc Acute brands like Pantakind (31%), Dydroboon (19%), Cefakind CV (18%), Nurokind LC (18%) in Q2FY27 \uf0fc Chronic brands like Pangraf (60%), Placida (28%), Telmikind AM (16%), Glizid M (15%) \uf0fc Healthy growth in BSVs key brands - Humog (51%), Lonopin (45 %), Anti D (37 %) and ASVS (45%) \uf0fc Brands with sales above Rs 50 crore increased to 63 in MAT Sep\u201926 from 54 in FY26, while brands with sales over Rs 100 crore rose to 26 from 22 \uf0b7 Consistently maintained #1 rank over last 9 years with prescription share of 15.2% and prescriber penetration of 84.4% in MAT Aug\u201926 1.As per IQVIA Sep-2026 \/\/ 2.Denotes reported number\/\/ 3. Ex-Tirzepatide Consumer Healthcare Business1 \uf0b7 Revenue growth impacted by slower offtake in category for the industry and some regional impact in East and South \uf0b7 Despite softer growth, we gained market share in key Brands \u2013 Manforce, and Preganews \uf0b7 MT & E-Com share increased to 18% in Q2FY27 as compared to 12% in Q2FY26 supported by 55% growth \uf0b7 Healthy growth in secondary sales for Preganews and Ova news of 14 % and 10 % YoY respectively in Q2 FY27 1 As per IQVIA \/ IQVIA Retail Sep-2026 Press Release Exports \uf0b7 International revenue increased by 33% in Q2FY27 driven by strong growth in both Mankind and BSV International \uf0b7 Mankind has launched 1 new product in Q2FY27 taking the total launched products to 50 in US Consolidated Profit & Loss Account Particulars (In INR Crore) Q2 FY27 Q2 FY26 YoY% Q1 FY27 QoQ% Revenue from Operations 4,338 3,697 17.3% 4,031 7.6% Gross Margins % 72.2% 71.3% 90 bps 72.8% (60 bps) EBITDA 1,175 924 27.2% 1,060 10.8% EBITDA Margin % 27.1% 25.0% 210 bps 26.3% 80 bps PAT 716 520 37.7% 574 24.7% PAT Margin % 16.5% 14.1% 240 bps 14.2% 230 bps Particulars (In INR Crore) H1 FY27 H1 FY26 YoY% Revenue from Operations 8,368 7,268 15.1% Gross Margins % 72.5% 70.9% 160 bps EBITDA 2,235 1,774 26.0% EBITDA Margin % 26.7% 24.4% 230 bps PAT 1,290 965 33.7% PAT Margin % 15.4% 13.3% 210 bps Segmental Revenue Break Up Particulars (In INR Crore) Q2 FY27 Q2 FY26 YoY% Q1 FY27 QoQ% Domestic 3,657 3,184 14.8% 3,426 6.7% \uf0b7 Domestic (Ex-CH) 3,428 2,958 15.9% 3,180 7.8% \uf0b7 Consumer Healthcare 229 226 1.2% 246 (7.0%) Exports 681 513 32.7% 605 12.6% Total 4,338 3,697 17.3% 4,031 7.6% Particulars (In INR Crore) H1 FY27 H1 FY26 YoY% Domestic 7,082 6,285 12.7% \uf0b7 Domestic (Ex-CH) 6,608 5,822 13.5% \uf0b7 Consumer Healthcare 475 463 2.6% Exports 1,286 982 31.0% Total 8,368 7,268 15.1% Press Release Earning Concall Details Date 26th October, 2026 Time 05:00 pm \u2013 06:00 pm IST Zoom Link Click here About Mankind Pharma Mankind Pharma (BSE: 543904 | NSE: MANKIND) is one of the largest pharmaceutical company in India, which focuses on the domestic market with its Pan India presence. Mankind operates at the intersection of the Indian pharmaceutical formulations and consumer healthcare sectors with the aim of providing quality products at affordable prices. The company is a leading player in the domestic pharmaceuticals business present across acute and chronic therapeutic areas including anti -infectives, cardiovascular, gastrointes tinal, antidiabetic, neuro\/CNS, gynaecology, VMN and respiratory, among others with a strategy to increase chronic presence going ahead. In the consumer healthcare business, the company operates in the condoms, pregnancy detection, emergency contraceptives, antacid powders, vitamin and mineral supplements and anti-acne preparations categories, among others, with several category -leading brands. Following the acquisition of BSV, Mankind Pharma has further strengthened its leadership in the domestic women\u2019s h ealth segment. Mankind's distribution network includes a robust field for ce of 18,500+ professionals, and a reach extending to over five lakh doctors across urban and rural markets. The company has 32 manufacturing facilities in India manufacturing a wide range of dosage forms, including tablets, capsules, syrups, vials, ampoules, blow fill seal, soft and hard gels, eye drops, creams, contraceptives and other over -the-counter products. Mankind has a consistent track record of product innovation through 7 dedicated R&D facilities backed by more than 740 scientists. For more information, visit www.mankindpharma.com Safe Harbour Statement The statements, are as on date and may contain forward -looking statements like the words \u201cbelieve\u201d, \u201cexpects\u201d, \u201canticipate\u201d, \u201caim\u201d, \u201cwill likely result\u201d, \u201cWould\u201d, \u201cwill continue\u201d, \u201ccontemplate\u201d \u201cintends\u201d, \u201cplans\u201d, \u201cestimates\u201d, \u201cseek to\u201d, \u201cfuture\u201d, \u201cobjective\u201d, \u201cprojects\u201d, \u201cgoal\u201d, \u201clikely\u201d, \u201cProject\u201d, \u201cshould\u201d, \u201cpotential\u201d \u201cwill\u201d , \u201cmay\u201d, \u201ctargeting\u201d or other words of similar expressions\/ meaning regarding the financial position, business strategy, plans, targets and objectives of the Company. Such forward\u2010 looking statements involve known and unknown risks which may cause actual results, performance or achievements to be materially different from the results or achievements expressed or implied. The risks and uncertainties inter-alia, relating to these statements include (i) cash flow projections, (ii) industry and market conditions; (iii) ability to manage growth; (iv) competition; (v) government policies and regulations; (vi) obtaining regulatory approvals; (vii) domestic & international economic Press Release conditions such as interest rate & currency exchange fluctuations; (viii) political, economic, legal and social conditions in India\/ elsewhere; (ix) technological advances; (x) claims and concerns about product safety and efficacy; (xi) domestic and foreign healthcare reforms; (xii) inability to build production capacity; (xiii) unavailabi lity of raw materials and failure to gain market acceptance The Company and its subsidiaries shall not have any responsibility or liability whatsoever for any loss howsoever arising from this presentation or its contents or otherwise arising in connection therewith. Also, Company assume no responsibility to publicly amend, modify or revise any forward looking statements, on the basis of any subsequent developments, information or events, or otherwise. For Queries Contact Mankind Pharma - Investor Relations Prakash Agarwal Email address: investor.relations@mankindpharma.com Contact Number: +91-11-46846700 Mankind Pharma - Corporate Communication Natasha Raj Email address: natasha.raj@mankindpharma.com Contact Number: 011-46846700 Ext: 3201 Adfactors PR - Investor Relations \/ Public Relations Smit Shah \/ Apoorva Sharma Email address: smit.shah@adfactorspr.com \/ apoorva.sharma@adfactorspr.com Contact Number: +91 9870789596 \/ +91 9999739452\"},{\"title\":\"Scheme of Arrangement\",\"summary\":\"Please find attached outcome of Board Meeting where Board has noted the merger of MCPPL & UAPL\",\"source\":\"NSE\",\"published\":\"26-Oct-2026 15:17:39\",\"source_type\":\"official filing\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/MANKIND1_26102026151729_Outcome26102026sd.pdf\",\"disclosure_text\":\"\"},{\"title\":\"Outcome of Board Meeting\",\"summary\":\"Mankind Pharma Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.\",\"source\":\"NSE\",\"published\":\"26-Oct-2026 15:07:57\",\"source_type\":\"official filing\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/MANKIND1_26102026150743_Outcome26102026sd.pdf\",\"disclosure_text\":\"\"},{\"summary\":\"a press release dated October 26, 2026, titled \\\"Press Release on Financial Results for Q2 & H1 FY27\\\".\",\"category\":\"Press Release\",\"date\":\"26-Oct-2026 15:23:58\",\"source\":\"NSE filing\",\"industry\":null,\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/MANKIND1_26102026152348_CoverPRsd.pdf\",\"headline\":\"Earnings \/ operating update\",\"impact\":\"Earnings updates are directly relevant to valuation. Revenue growth, margins, profit growth and management guidance are the key items to compare with expectations.\",\"importance_score\":5,\"completeness_score\":3},{\"summary\":\"Mankind Pharma Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.\",\"category\":\"Outcome of Board Meeting\",\"date\":\"26-Oct-2026 15:07:57\",\"source\":\"NSE filing\",\"industry\":null,\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/MANKIND1_26102026150743_Outcome26102026sd.pdf\",\"headline\":\"Earnings \/ operating update\",\"impact\":\"Earnings updates are directly relevant to valuation. Revenue growth, margins, profit growth and management guidance are the key items to compare with expectations.\",\"importance_score\":5,\"completeness_score\":4},{\"summary\":\"Mankind Pharma Limited has submitted the Exchange a copy Srutinizers report of Postal Ballot. Further, the company has informed the Exchange regarding voting results.\",\"category\":\"Shareholders meeting\",\"date\":\"17-Sep-2026 19:07:36\",\"source\":\"NSE filing\",\"industry\":null,\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/MANKIND1_17092026190722_Covering_SD.pdf\",\"headline\":\"Earnings \/ operating update\",\"impact\":\"Earnings updates are directly relevant to valuation. Revenue growth, margins, profit growth and management guidance are the key items to compare with expectations.\",\"importance_score\":5,\"completeness_score\":5},{\"summary\":\"a press release dated October 15, 2026, titled \\\"Press Release titled Mankind Pharma to Acquire Majority Stake in Armed Cell Therapeutics, Marking Strategic Entry into Next-Generation CAR-T Therapies \\\".\",\"category\":\"Press Release\",\"date\":\"15-Oct-2026 19:33:16\",\"source\":\"NSE filing\",\"industry\":null,\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/MANKIND1_15102026193306_Outcomefinalsd.pdf\",\"headline\":\"Investment \/ acquisition update\",\"impact\":\"The transaction can affect growth strategy, capital allocation or market access. Investors should consider the size of the investment, ownership acquired and expected returns.\",\"importance_score\":4,\"completeness_score\":3}],\"recent_news\":[{\"summary\":\"a press release dated October 26, 2026, titled \\\"Press Release on Financial Results for Q2 & H1 FY27\\\".\",\"category\":\"Press Release\",\"date\":\"26-Oct-2026 15:23:58\",\"source\":\"NSE filing\",\"industry\":null,\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/MANKIND1_26102026152348_CoverPRsd.pdf\",\"headline\":\"Earnings \/ operating update\",\"impact\":\"Earnings updates are directly relevant to valuation. Revenue growth, margins, profit growth and management guidance are the key items to compare with expectations.\",\"importance_score\":5,\"completeness_score\":3},{\"summary\":\"Mankind Pharma Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.\",\"category\":\"Outcome of Board Meeting\",\"date\":\"26-Oct-2026 15:07:57\",\"source\":\"NSE filing\",\"industry\":null,\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/MANKIND1_26102026150743_Outcome26102026sd.pdf\",\"headline\":\"Earnings \/ operating update\",\"impact\":\"Earnings updates are directly relevant to valuation. Revenue growth, margins, profit growth and management guidance are the key items to compare with expectations.\",\"importance_score\":5,\"completeness_score\":4},{\"summary\":\"Mankind Pharma Limited has submitted the Exchange a copy Srutinizers report of Postal Ballot. Further, the company has informed the Exchange regarding voting results.\",\"category\":\"Shareholders meeting\",\"date\":\"17-Sep-2026 19:07:36\",\"source\":\"NSE filing\",\"industry\":null,\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/MANKIND1_17092026190722_Covering_SD.pdf\",\"headline\":\"Earnings \/ operating update\",\"impact\":\"Earnings updates are directly relevant to valuation. Revenue growth, margins, profit growth and management guidance are the key items to compare with expectations.\",\"importance_score\":5,\"completeness_score\":5},{\"summary\":\"a press release dated October 15, 2026, titled \\\"Press Release titled Mankind Pharma to Acquire Majority Stake in Armed Cell Therapeutics, Marking Strategic Entry into Next-Generation CAR-T Therapies \\\".\",\"category\":\"Press Release\",\"date\":\"15-Oct-2026 19:33:16\",\"source\":\"NSE filing\",\"industry\":null,\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/MANKIND1_15102026193306_Outcomefinalsd.pdf\",\"headline\":\"Investment \/ acquisition update\",\"impact\":\"The transaction can affect growth strategy, capital allocation or market access. Investors should consider the size of the investment, ownership acquired and expected returns.\",\"importance_score\":4,\"completeness_score\":3}],\"promoter_pledge\":{\"summary\":\"Completion of Realignment of Security Cover in respect of Non-ConvertibleDebentures and Consequent Release of Pledged Shares of Bharat Serums andVaccines Limited\",\"events\":[{\"summary\":\"Completion of Realignment of Security Cover in respect of Non-ConvertibleDebentures and Consequent Release of Pledged Shares of Bharat Serums andVaccines Limited\",\"category\":\"General Updates\",\"date\":\"17-Aug-2026 23:09:34\",\"source\":\"NSE corporate filing\",\"attachment\":\"https:\/\/nsearchives.nseindia.com\/corporate\/MANKIND1_17082026230916_Intimation_to_Stk_Exchnage_for_release_of_pledge.pdf\",\"detail_level\":\"pdf_facts\"},{\"summary\":\", Mumbai \u2013 400 001 Scrip Code: 543904 National Stock Exchange of India Limited Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai \u2013 400 051 Symbol: MANKIND Dear Sir\/ Madam, Subject: Disclosures under Regulation 31(4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 Pursuant to Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, we, Promoter and Promoter Group along with persons acting in concert (enclosed as Annexure-1) of Mankind Pharma Limited (\u201cCompany\u201d), do hereby confirm that we have not made any encumbrance on the shares held by us in Company, directly or indirectly, during the financial year ended on March 31, 2026. This is for your information and records. For and on behalf of Promoters and Promoter Group of Mankind Pharma Limited Ramesh Juneja Promoter Encl.: A\/a Copy to: The Audit Committee Mankind Pharma Limited 208, Okhla Industrial Estate, Phase-III, New Delhi, Delhi, 110020 Annexure-1 List of Promoters, Promoter Group and Persons Acting in Concert of Mankind Pharma Limited: S. No. Name Promoter\/Promoter Group 1. Ramesh Juneja Promoter 2. Rajeev Juneja Promoter 3. Sheetal Arora\",\"category\":\"Disclosure under SEBI Takeover Regulations\",\"date\":\"10-Jun-2026 15:56:55\",\"source\":\"NSE corporate filing\",\"attachment\":\"https:\/\/nsearchives.nseindia.com\/corporate\/team_bbodade_29052026181816_MANKIND.pdf\",\"detail_level\":\"pdf_facts\"}],\"source\":\"NSE corporate filing\"},\"shareholding_snapshot\":{\"promoter_pct\":72.62,\"public_pct\":27.38,\"fii_pct\":9.37,\"dii_pct\":15.56,\"mf_pct\":11.31,\"institutional_pct\":24.93,\"noninst_pct\":2.45,\"mf_scheme_count\":36,\"pledged_shares\":null,\"pledged_pct_of_promoter\":null,\"mf_holders\":[{\"name\":\"NIPPON LIFE INDIA TRUSTEE LTD-A\/C NIPPON INDIA RET\",\"shares\":10127458,\"pct\":2.45},{\"name\":\"SBI ESG EXCLUSIONARY STRATEGY FUND\",\"shares\":6144507,\"pct\":1.49},{\"name\":\"ADITYA BIRLA SUN LIFE MUTUAL FUND - ADITYA BIRLA S\",\"shares\":4997240,\"pct\":1.21}],\"period\":\"30-SEP-2026\",\"submission_date\":\"16-OCT-2026\",\"source\":\"NSE shareholding pattern XBRL\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/xbrl\/SHP_1740145_16102026052126_WEB.xml\",\"previous_period\":\"30-JUN-2026\",\"previous_promoter_pct\":72.63,\"previous_fii_pct\":9.45,\"previous_dii_pct\":15.39,\"previous_mf_pct\":10.87,\"previous_institutional_pct\":24.84,\"previous_mf_scheme_count\":36,\"previous_pledged_pct_of_promoter\":null,\"previous_pledged_shares\":null}} --><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Mankind Pharma share price rose 4.49% to \u20b92,312.00 today. See why MANKIND is rising, volume context, company developments and what to watch next.<\/p>\n","protected":false},"author":1,"featured_media":8768,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"_witty_seo_title":"Mankind Pharma Share Price Today: Why MANKIND Is Rising 4.49% | 26 October 2026","_witty_meta_description":"Mankind Pharma share price rose 4.49% to \u20b92,312.00 today. See why MANKIND is rising, volume context, company developments and what to watch next.","_witty_primary_phrase":"Mankind Pharma share price today","_witty_reason_label":"strong Q2 financial results and sector momentum","_witty_reason_confidence":"high","footnotes":"","_yoast_wpseo_title":"","_yoast_wpseo_metadesc":"","_yoast_wpseo_focuskw":"","rank_math_title":"","rank_math_description":"","rank_math_focus_keyword":"","_aioseop_title":"","_aioseop_description":""},"categories":[3,4],"tags":[32],"class_list":["post-8769","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-market-movers","category-stocks-in-news","tag-mankind"],"_links":{"self":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/8769","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/comments?post=8769"}],"version-history":[{"count":2,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/8769\/revisions"}],"predecessor-version":[{"id":8879,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/8769\/revisions\/8879"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/media\/8768"}],"wp:attachment":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/media?parent=8769"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/categories?post=8769"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/tags?post=8769"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}